Compare American Electric Power Company Inc (AEP) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Electric Power Company Inc vs BioNTech SE - ADR — how do they compare? American Electric Power Company Inc trades at $123.69 (market cap $67.28B), while BioNTech SE - ADR trades at $92.94 (market cap $23.31B). The key difference: American Electric Power Company Inc is far larger — about 2.9× BioNTech SE - ADR's market cap, and American Electric Power Company Inc pays a 3.07% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| AEP | BNTX | |
|---|---|---|
Market Cap | $67.28B | $23.31B |
Sector | Utilities | Health |
52-Week High | $138.69 | $119.34 |
52-Week Low | $106.44 | $83.89 |
Enterprise Value | $120.17B | $6.60B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEP trades at $124.17, up 1.08% today, with a bearish technical signal but strong fundamentals. Recent Q2 2026 EPS missed estimates at $1.36 versus $1.48 expected, yet revenue grew 7% year-over-year. The company raised 2026 operating EPS guidance to $6.25–$6.55, supported by a $78 billion capital plan and 69 GW of contracted load growth. Analyst consensus is bullish with a $140.89 price target, and dividends remain stable with a $0.95 payment scheduled for September 2026.
Outlook is positive due to robust demand from data centers and regulatory progress, but risks include high debt levels and interest expenses. The stock offers growth potential from AI-driven electricity demand, though valuation premiums and execution risks warrant caution. Near-term support lies at $121, with resistance at $126.
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Electric Power Company Inc
American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 43% of AEP's of capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (19%), nuclear (7%), and demand response (4%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.
Read more on AEP →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
